Laurus Labs Limited (LAURUSLABS.NS)

Healthcare | Drug Manufacturers Specialty Generic
Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$17.8B

Net Income

$2.5B

Operating Margin

20.2%

Free Cash Flow

-$394M

Debt / Assets

50.7%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Laurus Labs Limited (LAURUSLABS.NS).
Income Statement (Quarterly) 2025-12-31 2025-09-30 2025-06-30 2024-12-31
Revenue 17,782,900,000 16,534,700,000 15,695,700,000 14,150,500,000
Cost of Revenue 10,444,300,000 9,994,900,000 6,373,500,000 6,101,500,000
Gross Profit 7,338,600,000 6,539,800,000 9,322,200,000 8,049,000,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 3,052,700,000 3,022,100,000 2,148,000,000 0
Operating Expenses 3,742,700,000 3,712,100,000 2,148,000,000 6,258,400,000
Operating Income 3,595,900,000 2,827,700,000 7,174,200,000 1,790,600,000
Interest Expense 387,900,000 400,000,000 515,000,000 578,000,000
Income Before Tax 3,253,300,000 2,704,700,000 2,248,200,000 1,306,800,000
Income Tax Expense 734,500,000 759,800,000 631,400,000 400,700,000
Net Income 2,516,600,000 1,949,700,000 1,630,200,000 923,000,000
Per Share
EPS 4.66 3.61 3.02 1.71
EPS Diluted 0.00 0.00 0.00 0.00